Edition:
United States

Sun Pharmaceutical Industries Ltd (SUN.NS)

SUN.NS on National Stock Exchange of India

641.55INR
20 Jan 2017
Change (% chg)

Rs-1.90 (-0.30%)
Prev Close
Rs643.45
Open
Rs642.85
Day's High
Rs647.40
Day's Low
Rs640.00
Volume
3,671,360
Avg. Vol
3,867,321
52-wk High
Rs898.45
52-wk Low
Rs571.90

Select another date:

Tue, Dec 13 2016

Photo

FDA finds quality control problems at Sun Pharma's Halol plant

MUMBAI The U.S. Food and Drug Administration (FDA) has again raised concerns about the quality control process at Indian drugmaker Sun Pharmceutical Industries' Halol factory, an inspection report obtained by Reuters shows.

India's Sun Pharma says U.S. finds more concerns at Halol plant

MUMBAI Sun Pharmaceutical Industries Ltd, India's largest drugmaker, said on Wednesday the U.S. health regulator has informed the company of more concerns found at its Halol manufacturing plant after a recent inspection.

BRIEF-Sun Pharma Industries launches first branded ophthalmic product Bromsite in USA

* Announcement of launches first branded ophthalmic product Bromsite in USA

BRIEF-Sun Pharma enters into deal to buy 85.1 pct of Russia's JSC Biosintez

* Says company has entered into an agreement to acquire 85.1% of JSC Biosintez, a Russian pharmaceutical company

UPDATE 2-Sun Pharma expects U.S. drug pricing pressures to continue

* Says expects pricing pressure in U.S. to continue (Adds comments from conference call)

BRIEF-India's Sun Pharma says unsure if Halol plant will be cleared in next 5 months

* India's Sun Pharma said it was unsure if Halol plant would be cleared in the next five months, as the FDA may take time Further company coverage: (Reporting By Zeba Siddiqui)

BRIEF-Sun Pharmaceutical Industries exec says pricing pressure in the U.S. will continue

* Sun Pharmaceutical Industries exec says awaiting US FDA reinspection of Halol plant

India's Sun Pharma Q2 profit beats estimates

MUMBAI, Nov 10 Sun Pharmaceutical Industries Ltd , India's largest drugmaker, reported on Thursday a quarterly profit that more than doubled from last year, outpacing analysts' expectations.

BRIEF-Sun Pharmaceutical Industries approves amalgamation of 4 units into co

* Says approves scheme of amalgamation of Sun Pharma Medisales, Ranbaxy Drugs Ltd, Gufic Pharma, Vidyut Investments into co Source text: http://bit.ly/2g0Jbpb Further company coverage:

BRIEF-Sun Pharmaceutical Industries on track to achieve benefits from Ranbaxy acquisition

* Sun Pharmaceutical Industries Ltd says synergies from the Ranbaxy acquisition are gaining momentum and co on track to achieve the targeted benefits

Select another date: